Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer

Our recent studies using comparative genomic hybridization showed that gain or amplification at the 17q12–q21 region is very common in the intestinal type of gastric cancer. Here, we describe a fluorescence in situ hybridization study with gastrin (GAS)‐specific and ERBB2‐specific probes on ten spec...

Full description

Saved in:
Bibliographic Details
Published inGenes chromosomes & cancer Vol. 24; no. 1; pp. 24 - 29
Main Authors Vidgren, Virve, Varis, Asta, Kokkola, Arto, Monni, Outi, Puolakkainen, Pauli, Nordling, Stig, Forozan, Farahnaz, Kallioniemi, Anne, Vakkari, Marja-Leena, Kivilaakso, Eero, Knuutila, Sakari
Format Journal Article
LanguageEnglish
Published New York John Wiley & Sons, Inc 01.01.1999
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Our recent studies using comparative genomic hybridization showed that gain or amplification at the 17q12–q21 region is very common in the intestinal type of gastric cancer. Here, we describe a fluorescence in situ hybridization study with gastrin (GAS)‐specific and ERBB2‐specific probes on ten specimens of gastric carcinoma that, by using comparative genomic hybridization, showed 1) DNA copy number gain or amplification at 17q12–q21, a region known to harbor the GAS and ERBB2 genes (four cases); 2) gain of the entire chromosome 17 (three cases); or 3) normal copy number of chromosome 17 (three cases). GAS and ERBB2 protein expression was studied by Western immunoblotting from gastric cancer cell lines with or without gain at 17q12–q21 as well as a breast cancer cell line with ERBB2 amplification. Our results showed that simultaneous amplification of both GAS and ERBB2 was four‐ to ninefold in the tumors with the 17q12–q21 amplification. Both genes were amplified in the same nuclei, and the hybridization signals were localized to the same region of the nucleus. Overexpression of GAS and ERBB2 was observed by Western immunoblotting only in the gastric cancer cell line with gain at 17q12–q21. The ERBB2 amplification is also a recurrent change in breast cancer. To investigate whether the GAS amplification is unique in gastric cancer, fluorescence in situ hybridization analysis was performed on 40 breast cancer cell lines. The ERBB2 amplification was observed in 11 cell lines, but none of the lines showed the GAS amplification. This indicates that the formation of an amplicon, in which both the GAS and the ERBB2 genes are amplified, might be unique in gastric cancer, especially in its intestinal type, and that simultaneous amplification of both genes is important to the tumorigenesis of intestinal gastric cancer. We demonstrate here for the first time that a gene of a physiological hormone is amplified in tumors that originate from cells that normally secrete the hormone. Genes Chromosomes Cancer 24:24–29, 1999. © 1999 Wiley‐Liss, Inc.
Bibliography:The Finnish Cancer Society
istex:8F4306B6BA8BC60C872F523D0932FF7BB680AB1C
Virve Vidgren and Asta Varis contributed equally to this work.
ArticleID:GCC4
ark:/67375/WNG-JT2S3RPV-D
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1045-2257
1098-2264
DOI:10.1002/(SICI)1098-2264(199901)24:1<24::AID-GCC4>3.0.CO;2-H